As children with growth disorders need to have r-GH therapy for many years to achieve clinically significant outcomes, the development of a digital health ecosystem that connects patients, caregivers, and HCPs provides better opportunities for remote patient management, improved patient engagement, better adherence to therapy, and the adoption of a precision medicine approach tailored to the needs of the patient. This evidence concerns the gene GH1 and hereditary endocrine growth disease.